Orgenesis Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Orgenesis şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-55.4%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-55.4%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Orgenesis Inc.'s (NASDAQ:ORGS) Price Is Right But Growth Is Lacking After Shares Rocket 119%

Mar 04

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: ORGS şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: ORGS şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Orgenesis Piyasaya Karşı Temettü Getirisi

ORGS temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (ORGS)	n/a
Pazarın Alt %25'i (US)	1.3%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (ORGS) (3 yıla kadar)	n/a

Önemli Temettü: ORGS şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, ORGS şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: ORGS şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: ORGS herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Orgenesis Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Orgenesis Inc. Announces Resignation of Mark Goodman as Director

The Nasdaq Hearings Panel Determines to Delist Orgenesis Common Stock

Orgenesis Announces 1-For-10 Reverse Stock Split to Regain Nasdaq Compliance

Orgenesis Announces Positive Results from Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia

Less than half of directors are independent

The Nasdaq Hearings Panel Grants Extension Until October 14, 2024 to Orgenesis to Regain Compliance with the Bid Price and Equity Rules

Orgenesis Inc. announced delayed 10-Q filing

Orgenesis Inc., Annual General Meeting, Jun 27, 2024

Orgenesis Receives Non-Compliance Letter from Nasdaq

Orgenesis Inc. announced delayed annual 10-K filing

Orgenesis Inc.'s (NASDAQ:ORGS) Price Is Right But Growth Is Lacking After Shares Rocket 119%

Orgenesis Inc. announced that it expects to receive $2.340901 million in funding

Orgenesis Inc. (NasdaqCM:ORGS) agreed to acquire 25% stake in Octomera LLC from MM OS Holdings, L.P.

Orgenesis Inc. Announces Chief Financial Officer Changes

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Orgenesis Inc. has filed a Follow-on Equity Offering in the amount of $1.1 million.

Orgenesis Inc. has filed a Follow-on Equity Offering in the amount of $1.1 million.

Orgenesis Receives Non-Compliance Notice From Nasdaq

Orgenesis Inc. announced that it has received $1 million in funding

New minor risk - Share price stability

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Orgenesis Inc. Announces Executive Changes, Effective September 1, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Orgenesis Inc. and Kurve Therapeutics Announce Pre-Clinical Study Results for A Cell-Based Oncolytic Virus Bearing Product Demonstrating over 50% Reduction in A Murine Glioblastoma Model

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Orgenesis Inc., Annual General Meeting, Dec 15, 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Orgenesis GAAP EPS of $0.22 beats by $0.24, revenue of $7.2M beats by $0.2M

Orgenesis Inc. announced delayed 10-Q filing

Forecast to breakeven in 2023

Orgenesis Inc. announced that it has received $14.799999 million in funding

Orgenesis Inc. announced that it expects to receive $14.799999 million in funding

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Orgenesis Inc. to Report Fiscal Year 2021 Results on Mar 30, 2022

Orgenesis Inc. to Report Fiscal Year 2021 Results on Mar 30, 2022

Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.43 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$1.26 loss in 2Q 2020)

Orgenesis Inc.(NasdaqCM:ORGS) dropped from Russell 3000E Value Index

Orgenesis Enrollment Commences for Clinical Trial Using the Tissue Genesis Icellator® At the Hospital for Special Surgery in New York

First quarter 2021 earnings released: US$0.009 loss per share (vs US$0.42 loss in 1Q 2020)

FDA Approves Orgenesis IDE for Pilot Clinical Trial of its Tissue Genesis Icellator2 to Treat ARDS Resulting from COVID-19 Infection

Orgenesis gets FDA IDE approval for Tissue Genesis Icellator COVID-19 study

Orgenesis shares rise after Bambino Gesù Children's Hospital collaboration

Orgenesis Enters Second Phase of Collaboration with Hospital Infantil Universitario Niño Jesús in Madrid with Exclusive License to Commercialize Celyvir Solid Tumor Therapy

Full year 2020 earnings released: US$4.46 loss per share (vs US$1.77 loss in FY 2019)

Orgenesis Inc., Dong-A University Hospital and Cure Therapeutics, Inc. Signs Collaboration Agreement

New 90-day high: US$7.15

Orgenesis (NASDAQ:ORGS) Has Debt But No Earnings; Should You Worry?

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin